Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of irritable bowel syndrome (IBS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IBS for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key irritable bowel syndrome patient populations, covering 171…

Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…

Clarivate Epidemiology’s coverage of beta thalassemia (BT) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of T2D for each…

Clarivate Epidemiology’s coverage of polycystic ovarian syndrome (PCOS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…

Clarivate Epidemiology’s coverage of myelofibrosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of post-traumatic stress disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of post…

Clarivate Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key squamous cell carcinoma of the head and neck patient populations,…

Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…